{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:22:09Z","timestamp":1783527729496,"version":"3.55.0"},"reference-count":78,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Multiple myeloma (MM) is a complex hematologic malignancy characterized by abnormal plasma cell proliferation in the bone marrow. [18F]FDG PET\/CT has emerged as a key imaging modality, demonstrating high sensitivity and specificity for the detection of metabolically active disease compared with conventional imaging techniques. This review examines the role of PET\/CT imaging in evaluating therapeutic response in symptomatic myeloma, including minimal residual disease (MRD) assessment. Methods: We surveyed the literature published between 2014 and 2024 across PubMed, Scopus, Web of Science, and the Cochrane Library for peer-reviewed articles evaluating PET imaging in the assessment of treatment response in multiple myeloma. Results: [18F]FDG PET\/CT provides a whole-body assessment of disease burden, extramedullary involvement detection, and early metabolic response evaluation. Standardized response assessment criteria (Deauville, IMPeTUs, IMWG) have enhanced the reproducibility and accuracy of treatment monitoring. Semiquantitative parameters including SUVmax and metabolic tumor volume (MTV) provide useful prognostic information with PET negativity correlating with improved progression-free and overall survival. The integration of PET\/CT with bone marrow assessment techniques (next-generation flow cytometry and sequencing) optimizes MRD evaluation and patient stratification. Conclusions: PET\/CT represents a valuable imaging tool for improving therapeutic decision making and risk stratification in MM management. Emerging radiotracers beyond FDG, including [11C]choline, [11C]methionine, and targeted agents like [68Ga]pentixafor and CD38-targeted immunoPET tracers, hold promise for enhanced diagnostic capabilities in specific clinical contexts.<\/jats:p>","DOI":"10.3390\/cancers18142184","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:40:09Z","timestamp":1783525209000},"page":"2184","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PET\/CT Imaging for Therapy Assessment in Multiple Myeloma Including MRD"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2034-0531","authenticated-orcid":false,"given":"Alessia Lucia","family":"Daverio","sequence":"first","affiliation":[{"name":"Service de M\u00e9decine Nucl\u00e9aire, D\u00e9partement d\u2019Imagerie M\u00e9dicale, Institut Gustave Roussy, F-94805 Villejuif, France"},{"name":"Nuclear Medicine Division, AOU Citt\u00e0 della Salute e della Scienza di Torino, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Coccarelli","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, AOU Citt\u00e0 della Salute e della Scienza di Torino, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0672-415X","authenticated-orcid":false,"given":"Th\u00e9ophraste","family":"Henry","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Nucl\u00e9aire, D\u00e9partement d\u2019Imagerie M\u00e9dicale, Institut Gustave Roussy, F-94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Danu","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Hematologie, Institut Gustave Roussy, F-94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8831-9133","authenticated-orcid":false,"given":"Laurentiu","family":"Agrigoroaie","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Nucl\u00e9aire, D\u00e9partement d\u2019Imagerie M\u00e9dicale, Institut Gustave Roussy, F-94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Trabelsi","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Nucl\u00e9aire, D\u00e9partement d\u2019Imagerie M\u00e9dicale, Institut Gustave Roussy, F-94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Kamoun","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Nucl\u00e9aire, D\u00e9partement d\u2019Imagerie M\u00e9dicale, Institut Gustave Roussy, F-94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1839-0206","authenticated-orcid":false,"given":"Guido","family":"Rovera","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Nucl\u00e9aire, D\u00e9partement d\u2019Imagerie M\u00e9dicale, Institut Gustave Roussy, F-94805 Villejuif, France"},{"name":"Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7833-6095","authenticated-orcid":false,"given":"Silvia","family":"Morbelli","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, AOU Citt\u00e0 della Salute e della Scienza di Torino, University of Turin, 10126 Turin, Italy"},{"name":"Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"Deandreis","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Nucl\u00e9aire, D\u00e9partement d\u2019Imagerie M\u00e9dicale, Institut Gustave Roussy, F-94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple Myeloma","volume":"385","author":"Knop","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2214\/AJR.21.25878","article-title":"Updates and Ongoing Challenges in Imaging of Multiple Myeloma: AJR Expert Panel Narrative Review","volume":"217","author":"Wu","year":"2021","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","article-title":"Role of Magnetic Resonance Imaging in the Management of Patients with Multiple Myeloma: A Consensus Statement","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the Diagnosis and Management of Multiple Myeloma and Other Plasma Cell Disorders: A Consensus Statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International Myeloma Working Group Consensus Recommendations on Imaging in Monoclonal Plasma Cell Disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN Guidelines\u00ae Insights: Multiple Myeloma, Version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab before and after Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, Dexamethasone, and Daratumumab versus Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (CANDOR): Results from a Randomised, Multicentre, Open-Label, Phase 3 Study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, Carfilzomib, and Dexamethasone in Relapsed Multiple Myeloma (IKEMA): A Multicentre, Open-Label, Randomised Phase 3 Trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.2217\/fon-2022-1317","article-title":"Cilta-Cel, a BCMA-Targeting CAR-T Therapy for Heavily Pretreated Patients with Relapsed\/Refractory Multiple Myeloma","volume":"19","author":"Martin","year":"2023","journal-title":"Future Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"15353508241257924","DOI":"10.1177\/15353508241257924","article-title":"PET\/CT in the Evaluation of CAR-T Cell Immunotherapy in Hematological Malignancies","volume":"23","author":"Singh","year":"2024","journal-title":"Mol. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International Harmonization in Performing and Reporting Minimal Residual Disease Assessment in Multiple Myeloma Trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/j.semnuclmed.2022.10.008","article-title":"Clinical Value of FDG-PET\/CT in Multiple Myeloma: An Update","volume":"53","author":"Bezzi","year":"2023","journal-title":"Semin Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ishibashi, M., Takahashi, M., Yamaya, T., and Imai, Y. (2023). Current and Future PET Imaging for Multiple Myeloma. Life, 13.","DOI":"10.3390\/life13081701"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1016\/S2352-3026(23)00030-3","article-title":"European Association of Nuclear Medicine (EANM) Focus 4 Consensus Recommendations: Molecular Imaging and Therapy in Haematological Tumours","volume":"10","author":"Nanni","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00259-024-06858-9","article-title":"EANM Guidelines on the Use of [18F]FDG PET\/CT in Diagnosis, Staging, Prognostication, Therapy Assessment, and Restaging of Plasma Cell Disorders","volume":"52","author":"Nanni","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.eclinm.2023.102017","article-title":"Impact of Minimal Residual Disease Standardised Assessment by FDG-PET\/CT in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Enrolled in the Imaging Sub-Study of the FORTE Trial","volume":"60","author":"Zamagni","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_26","first-page":"621","article-title":"Prognostic Value of Positron Emission Tomography\/Computed Tomography in Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients from CASSIOPEIA: The CASSIOPET Study","volume":"108","author":"Zweegman","year":"2023","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00330-012-2600-5","article-title":"Comparative Diagnostic Performance of 18F-FDG PET\/CT versus Whole-Body MRI for Determination of Remission Status in Multiple Myeloma after Stem Cell Transplantation","volume":"23","author":"Derlin","year":"2013","journal-title":"Eur. Radiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11604-018-0738-z","article-title":"Diagnostic Performance of 18F-FDG PET\/CT and Whole-Body MRI before and Early after Treatment of Multiple Myeloma: A Prospective Comparative Study","volume":"36","author":"Basha","year":"2018","journal-title":"Jpn. J. Radiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/RLU.0000000000003512","article-title":"Agreement Between 18F-FDG PET\/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma","volume":"46","author":"Alegre","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"109403","DOI":"10.1016\/j.ejrad.2020.109403","article-title":"The Utility of ADC Value in Diffusion-Weighted Whole-Body MRI in the Follow-up of Patients with Multiple Myeloma. Correlation Study with 18F-FDG PET-CT","volume":"133","author":"Paternain","year":"2020","journal-title":"Eur. J. Radiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1038\/s41375-023-01998-7","article-title":"Intensifying Treatment in PET-Positive Multiple Myeloma Patients after Upfront Autologous Stem Cell Transplantation","volume":"37","author":"Abildgaard","year":"2023","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Laval, V., Lumbreras-Fern\u00e1ndez, B., Aguado-Bueno, B., and G\u00f3mez-Le\u00f3n, N. (2024). Imaging of Multiple Myeloma: Present and Future. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010264"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low Expression of Hexokinase-2 Is Associated with False-Negative FDG-Positron Emission Tomography in Multiple Myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2214\/AJR.21.26381","article-title":"Comparative Performance of Whole-Body MRI and FDG PET\/CT in Evaluation of Multiple Myeloma Treatment Response: Systematic Review and Meta-Analysis","volume":"218","author":"Rama","year":"2022","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1007\/s00330-023-09593-1","article-title":"Hybrid Simultaneous Whole-Body 2-[18F]FDG-PET\/MRI Imaging in Newly Diagnosed Multiple Myeloma: First Diagnostic Performance and Clinical Added Value Results","volume":"33","author":"Jamet","year":"2023","journal-title":"Eur. Radiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"15353508241245265","DOI":"10.1177\/15353508241245265","article-title":"Combining Nuclear Medicine With Other Modalities: Future Prospect for Multimodality Imaging","volume":"23","author":"Archibald","year":"2024","journal-title":"Mol. Imaging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic Relevance of 18-F FDG PET\/CT in Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mesguich, C., Latrabe, V., Hulin, C., Lascaux, A., Bordenave, L., Hindi\u00e9, E., and Marit, G. (2021). Prospective Comparison of 18-FDG PET\/CT and Whole-Body MRI with Diffusion-Weighted Imaging in the Evaluation of Treatment Response of Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant. Cancers, 13.","DOI":"10.3390\/cancers13081938"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","article-title":"Metabolic Tumor Volume Assessed by 18F-FDG PET\/CT for the Prediction of Outcome in Patients with Multiple Myeloma","volume":"53","author":"Fonti","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13550-021-00846-y","article-title":"The Prognostic Significance of [18F]FDG PET\/CT in Multiple Myeloma According to Novel Interpretation Criteria (IMPeTUs)","volume":"11","author":"Sachpekidis","year":"2021","journal-title":"EJNMMI Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary Disease in Multiple Myeloma: A Systematic Literature Review","volume":"12","author":"Beksac","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic Implications of Serial 18-Fluoro-Deoxyglucose Emission Tomography in Multiple Myeloma Treated with Total Therapy 3","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1158\/1078-0432.CCR-18-0741","article-title":"Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of \u0394SUVmax in the FDG-Avid Patients of the IMAJEM Study","volume":"24","author":"Bailly","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/bloodadvances.2020004131","article-title":"Prognostic Impact of Posttransplant FDG PET\/CT Scan in Multiple Myeloma","volume":"5","author":"Kaddoura","year":"2021","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM\/DFCI 2009 Trial: Results of the IMAJEM Study","volume":"35","author":"Moreau","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/bloodadvances.2022007052","article-title":"Utility of PET\/CT in Assessing Early Treatment Response in Patients with Newly Diagnosed Multiple Myeloma","volume":"6","author":"Charalampous","year":"2022","journal-title":"Blood Adv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1007\/s00259-018-3997-0","article-title":"Prognostic Value of [18F]FDG-PET\/CT in Multiple Myeloma Patients before and after Allogeneic Hematopoietic Cell Transplantation","volume":"45","author":"Stolzenburg","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","article-title":"Treatment to Suppression of Focal Lesions on Positron Emission Tomography-Computed Tomography Is a Therapeutic Goal in Newly Diagnosed Multiple Myeloma","volume":"103","author":"Davies","year":"2018","journal-title":"Haematologica"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.3324\/haematol.2017.169235","article-title":"Long-Term CD38 Saturation by Daratumumab Interferes with Diagnostic Myeloma Cell Detection","volume":"102","author":"Oberle","year":"2017","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bjh.18249","article-title":"Minimal Residual Disease and Imaging-guided Consolidation Strategies in Newly Diagnosed and Relapsed Refractory Multiple Myeloma","volume":"198","author":"Tabares","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","article-title":"Concordance between Four European Centres of PET Reporting Criteria Designed for Use in Multicentre Trials in Hodgkin Lymphoma","volume":"37","author":"Barrington","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.20.00386","article-title":"Standardization of 18F-FDG-PET\/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma","volume":"39","author":"Zamagni","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Nanni, C. (2020). PET-FDG: Impetus. Cancers, 12.","DOI":"10.3390\/cancers12041030"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","article-title":"Image Interpretation Criteria for FDG PET\/CT in Multiple Myeloma: A New Proposal from an Italian Expert Panel. IMPeTUs (Italian Myeloma Criteria for PET USe)","volume":"43","author":"Nanni","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"101148","DOI":"10.1016\/j.beha.2020.101148","article-title":"Current and Potential Applications of Positron Emission Tomography for Multiple Myeloma and Plasma Cell Disorders","volume":"33","author":"Ulaner","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1477-7819-5-68","article-title":"11C-Choline vs. 18F-FDG PET\/CT in Assessing Bone Involvement in Patients with Multiple Myeloma","volume":"5","author":"Nanni","year":"2007","journal-title":"World J. Surg. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00259-016-3392-7","article-title":"18F-Fluorocholine versus 18F-Fluorodeoxyglucose for PET\/CT Imaging in Patients with Suspected Relapsing or Progressive Multiple Myeloma: A Pilot Study","volume":"43","author":"Balogova","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Morales-Lozano, M.I., Rodriguez-Otero, P., Sancho, L., Nu\u00f1ez-Cordoba, J.M., Prieto, E., Marcos-Jubilar, M., Rosales, J.J., Alfonso, A., Guillen, E.F., and San-Miguel, J. (2022). 11C-Methionine PET\/CT in Assessment of Multiple Myeloma Patients: Comparison to 18F-FDG PET\/CT and Prognostic Value. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179895"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12149-014-0931-9","article-title":"Comparison of (11)C-4\u2032-Thiothymidine, (11)C-Methionine, and (18)F-FDG PET\/CT for the Detection of Active Lesions of Multiple Myeloma","volume":"29","author":"Okasaki","year":"2015","journal-title":"Ann. Nucl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7150\/thno.13921","article-title":"11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement","volume":"6","author":"Lapa","year":"2016","journal-title":"Theranostics"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.7150\/thno.20491","article-title":"11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"key":"ref_64","first-page":"1592","article-title":"18F-FLT PET in Hematologic Disorders: A Novel Technique to Analyze the Bone Marrow Compartment","volume":"47","author":"Agool","year":"2006","journal-title":"J. Nucl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2967\/jnumed.113.131169","article-title":"11C-Acetate PET\/CT for Metabolic Characterization of Multiple Myeloma: A Comparative Study with 18F-FDG PET\/CT","volume":"55","author":"Ho","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"20406207211030369","DOI":"10.1177\/20406207211030369","article-title":"Case Series: MRD Negativity Assessment Using 11C-Acetate PET with 3-Weekly Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma","volume":"12","author":"Ngai","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"477","DOI":"10.15252\/emmm.201404698","article-title":"In Vivo Molecular Imaging of Chemokine Receptor CXCR4 Expression in Patients with Advanced Multiple Myeloma","volume":"7","author":"Herrmann","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[68Ga]Pentixafor-PET\/CT for Imaging of Chemokine Receptor CXCR4 Expression in Multiple Myeloma\u2014Comparison to [18F]FDG and Laboratory Values","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease","volume":"57","author":"Herrmann","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.7150\/thno.19050","article-title":"CXCR4-Directed Endoradiotherapy Induces High Response Rates in Extramedullary Relapsed Multiple Myeloma","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41598-021-03748-0","article-title":"Ablation of VLA4 in Multiple Myeloma Cells Redirects Tumor Spread and Prolongs Survival","volume":"12","author":"Hathi","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2967\/jnumed.122.264349","article-title":"First-in-Humans Evaluation of Safety and Dosimetry of 64Cu-LLP2A for PET Imaging","volume":"64","author":"Laforest","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1148\/radiol.2020192621","article-title":"CD38-Targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging","volume":"295","author":"Ulaner","year":"2020","journal-title":"Radiology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood-2017-09-807263","article-title":"Copper 64-Labeled Daratumumab as a PET\/CT Imaging Tracer for Multiple Myeloma","volume":"131","author":"Caserta","year":"2018","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1182\/bloodadvances.2020002603","article-title":"Identifying CD38+ Cells in Patients with Multiple Myeloma: First-in-Human Imaging Using Copper-64-Labeled Daratumumab","volume":"4","author":"Krishnan","year":"2020","journal-title":"Blood Adv."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"22486","DOI":"10.1021\/acsomega.3c00624","article-title":"89Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET Imaging of Multiple Myeloma and Lymphomas","volume":"8","author":"Michel","year":"2023","journal-title":"ACS Omega"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"107083","DOI":"10.1016\/j.cmpb.2022.107083","article-title":"Bone Marrow Segmentation and Radiomics Analysis of [18F]FDG PET\/CT Images for Measurable Residual Disease Assessment in Multiple Myeloma","volume":"225","author":"Milara","year":"2022","journal-title":"Comput. Methods Programs Biomed."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00259-020-05049-6","article-title":"Random Survival Forest to Predict Transplant-Eligible Newly Diagnosed Multiple Myeloma Outcome Including FDG-PET Radiomics: A Combined Analysis of Two Independent Prospective European Trials","volume":"48","author":"Jamet","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2184\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:52:18Z","timestamp":1783525938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":78,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142184"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142184","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}